Table 1.
Basic characteristic of 240 LA NPC patients.
| Characteristic | Nimotuzumab | Non-nimotuzumab | P |
|---|---|---|---|
| No (%) | No (%) | ||
| Gender | 0.073 | ||
| Male | 88 (73.3) | 74 (61.7) | |
| Female | 32 (26.7) | 46 (38.3) | |
| Age (years) | 0.792 | ||
| Range | 19-76 | 18-77 | |
| Median | 47 | 47 | |
| <50 | 71 (59.2) | 73 ((60.8) | |
| ≥ 50 | 49 (40.8) | 47 39.2) | |
| T stage * | 0.913 | ||
| T1 | 4 (3.3) | 4 (3.3) | |
| T2 | 16 (13.3) | 20 (16.7) | |
| T3 | 54 (45.0) | 52 (43.3) | |
| T4 | 46 (38.4) | 34 (28.3) | |
| N stage * | 0.652 | ||
| N0 | 11 (9.2) | 15 (12.5) | |
| N1 | 40 (33.3) | 32 (26.7) | |
| N2 | 59 (49.2) | 62 (51.7) | |
| N3 | 10 (8.3) | 11 (9.2) | |
| Clinical stage * | 0.293 | ||
| III | 67 (55.8) | 76 (63.3) | |
| IVA-b | 53 (44.2) | 44 (36.7) | |
| IC regimen | 0.176 | ||
| TPF | 42 (35.0) | 27 (22.5) | |
| TP | 32 (26.7) | 39 (32.5) | |
| GP | 4 (3.3) | 7 (5.8) | |
| PF | 42 (35.0) | 46 (38.3) | |
| AC | 0.420 | ||
| No | 40 (33.3) | 47 (39.2) | |
| Yes | 80 (66.7) | 73 (60.8) |
WHO: World Health Organization. ECOG: Eastern Cooperative Oncology Group.
*The 7th AJCC/UICC staging system.